Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy
Standard
Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy. / Fiedler, Walter.
In: BRIT J HAEMATOL, Vol. 204, No. 4, 04.2024, p. 1135-1136.Research output: SCORING: Contribution to journal › Comment/debate › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy
AU - Fiedler, Walter
N1 - © 2024 British Society for Haematology and John Wiley & Sons Ltd.
PY - 2024/4
Y1 - 2024/4
N2 - Patients with newly diagnosed acute myeloid leukaemia and severe acute complications, such as respiratory failure or sepsis, suffer from a high mortality rate when induction chemotherapy is delivered in an ICU setting. The report by Liang et al. implies that less intensive therapy with hypomethylating agents/venetoclax results in a lower mortality and morbidity rate whereby preserving efficacy in this patient group. Commentary on: Liang et al. Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukemia. Br J Haematol 2024;204:1219-1226.
AB - Patients with newly diagnosed acute myeloid leukaemia and severe acute complications, such as respiratory failure or sepsis, suffer from a high mortality rate when induction chemotherapy is delivered in an ICU setting. The report by Liang et al. implies that less intensive therapy with hypomethylating agents/venetoclax results in a lower mortality and morbidity rate whereby preserving efficacy in this patient group. Commentary on: Liang et al. Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukemia. Br J Haematol 2024;204:1219-1226.
U2 - 10.1111/bjh.19311
DO - 10.1111/bjh.19311
M3 - Comment/debate
C2 - 38228122
VL - 204
SP - 1135
EP - 1136
JO - BRIT J HAEMATOL
JF - BRIT J HAEMATOL
SN - 0007-1048
IS - 4
ER -